Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss shouldn't dominate your life; focus on confidence and social aspects. Celebrities like Theo James, Henry Cavill, and Ryan Reynolds also experience hair loss but remain attractive and successful.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

A 16-year-old is experiencing thinning hair at the front and shedding during showers. He is concerned about potential early baldness and is considering seeing a doctor and taking multivitamins.

Finasteride helped OP recover their hairline, and they did not use minoxidil. OP experienced significant hair regrowth with finasteride, similar to their father's experience.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.

An 18-year-old has been using topical finasteride and minoxidil for hair loss without noticeable improvement and is considering oral finasteride. Some users suggest starting oral finasteride at 18 is fine, especially if puberty is complete, while others recommend caution and consulting a specialist.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

A 23-year-old is seeking advice on starting Finasteride for hair loss, questioning its effectiveness, side effects, and long-term safety, including concerns about dosage, alternatives, and potential impacts on fertility and beard growth. They also inquire about the effectiveness of combining topical and oral treatments and the necessity of Finasteride for maintaining hair transplant results.

A user shared their hair loss journey, starting treatments with topical minoxidil and finasteride at 17, and later adding oral versions and dutasteride by age 20, but still experiencing hair loss. Others suggested that the treatments have likely slowed the progression, and some recommended considering a hair transplant or adjusting medication, while expressing concerns about the potential side effects of starting such treatments at a young age.

A 20-year-old FTM individual started finasteride for hair loss with initial success but experienced increased shedding after 7 months. They are considering oral minoxidil as advised by their doctor to address the worsening hair loss.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Dutasteride may affect semen parameters but not significantly enough to impact fertility unless baseline fertility is already low. Finasteride and minoxidil are used for hair regrowth, with no side effects reported by one user.

High-dose Lysine and Histidine supplements caused curly/kinky hair and shedding due to Elastin dysfunction. Minoxidil, white tea, and dark grape juice were mentioned as treatments to inhibit Elastase and mimic Lysyl Oxidase.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

Finasteride improved scalp hair but thinned beards for some users. Some suggest trying minoxidil on the beard, though results vary.

Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.

An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hair follicles from DHT.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

Homelessness is humorously proposed as a solution to hair loss due to less grooming and stress. Treatments like Minoxidil and Finasteride are discussed, with genetics and lifestyle also considered important factors.

The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

A 24-year-old male shared his 5.5-year progress using minoxidil and nearly 5 years on finasteride/dutasteride for hair loss, reporting no side effects and successful results. He uses 0.5 mg dutasteride daily, oral minoxidil 2.5 mg daily, and topical minoxidil daily, with costs around $4 monthly.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

A person has been using 1mg Finasteride for 20 years with no side effects but is now noticing temple thinning and is considering oral Minoxidil, despite concerns about heart health and body hair growth. They are consulting a doctor about possibly taking 1.25 to 2.5 mg of oral Minoxidil.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.